Dr Uwe Schlokat
Chief Executive Officer
Life Science
Sentinel Canada
Malaysia
Biography
Dr Uwe Schlokat received his Master’s degree and PhD in Molecular Biology from Heidelberg University, Germany. In a biotech career that has spanned over 25 years, he has carried out research at Genentech Inc (US), product development at Immuno AG (Austria), to global project program management at Baxter Healthcare (Austria). During this period, Dr Schlokat published and filed over 50 publications and patents, predominantly in the area of recombinantly produced therapeutic agents. In these different roles, he was responsible for driving new development or lifecycle products, including: ADVATE (recombinant FVIII), GAMMAGARD Liquid (plasma derived Immunoglobulins) and RIXUBIS (recombinant FIX) and was also involved in product development for devices such as BAXJECT II (reconstitution device) and vaccines such as ACAM 2000 (smallpox vaccine) for emergency stockpiling. In addition, Dr Schlokat’s team led the development of products such as recombinant von Willebrand Factor or Factor VIIa, currently in late Stage (Phase III) clinical development.
Research Interest
Drug Development
